Cogent Biosciences, Inc. (COGT)
36.23
-0.50
(-1.36%)
USD |
NASDAQ |
Aug 24, 16:00
36.23
0.00 (0.00%)
After-Hours: 19:52
Cogent Biosciences Total Liabilities (Quarterly) : 302.16M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 302.16M |
| March 31, 2026 | 295.31M |
| December 31, 2025 | 301.24M |
| September 30, 2025 | 123.47M |
| June 30, 2025 | 119.78M |
| March 31, 2025 | 64.80M |
| December 31, 2024 | 71.61M |
| September 30, 2024 | 69.36M |
| June 30, 2024 | 56.71M |
| March 31, 2024 | 53.78M |
| December 31, 2023 | 55.64M |
| September 30, 2023 | 52.55M |
| June 30, 2023 | 43.94M |
| March 31, 2023 | 39.64M |
| December 31, 2022 | 45.08M |
| September 30, 2022 | 41.62M |
| June 30, 2022 | 46.67M |
| March 31, 2022 | 19.01M |
| Date | Value |
|---|---|
| December 31, 2021 | 17.91M |
| September 30, 2021 | 18.15M |
| June 30, 2021 | 15.71M |
| March 31, 2021 | 10.85M |
| December 31, 2020 | 16.25M |
| September 30, 2020 | 162.04M |
| June 30, 2020 | 11.81M |
| March 31, 2020 | 13.24M |
| December 31, 2019 | 17.66M |
| September 30, 2019 | 29.26M |
| June 30, 2019 | 29.55M |
| March 31, 2019 | 31.99M |
| December 31, 2018 | 25.69M |
| September 30, 2018 | 27.26M |
| June 30, 2018 | 26.05M |
| March 31, 2018 | 27.52M |
| December 31, 2017 | 20.81M |
| September 30, 2017 | 21.91M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 141.21M |
| ImmunityBio, Inc. | 1.674B |
| Erasca, Inc. | 73.18M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 834.55M |
| Shareholders Equity (Quarterly) | 532.39M |
| Debt to Equity Ratio | 0.4588 |
| Current Ratio | 13.57 |
| Net Debt Paydown Yield | -0.68% |